A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease

Andrea Vambutas13 enrolled

Overview

The purpose of this study is to determine if Anakinra (an interleukin-1 receptor antagonist) can improve hearing thresholds in those patients with Autoimmune Inner Ear Disease (AIED) that did not respond to oral steroid therapy for a sudden decline in hearing. The patients to be enrolled will have recently completed a course of oral steroids and demonstrated no change in their audiometric thresholds following corticosteroid therapy.

Patients with immune mediated hearing loss (also known as autoimmune hearing loss) are typically treated with corticosteroids. Of those treated, approximately 60% respond, however, that response may be lost over time. Other therapies use to date have proven largely ineffectual in improving hearing. This study proposes a phase I open label clinical trial of Anakinra for corticosteroid-resistant patients to determine if this therapy is efficacious in hearing restoration.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Sensorineural Hearing Loss Autoimmune Inner Ear Disease

Interventions

AnakinraDRUG

100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.

Eligibility

Sex: ALLMin age: 13 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Bilateral sensorineural hearing loss with an active decline in hearing in one ear * No audiometric improvement with 28-30 days of oral prednisone or other corticosteroid, including an initial dose of 60mg per day for 14 days * Enrollment within 14 days of completion of corticosteroid therapy * Age 13 years and older * No evidence of neutropenia (low white blood cell count) * No evidence of retrocochlear pathology (ie. acoustic neuroma/vestibular schwannoma) * May have concurrent, systemic autoimmune disease Exclusion Criteria: * Age over 75, or less than 13 * Neutropenia * Renal insufficiency * Pregnant females * Unilateral hearing loss * Patients with any immunodeficiency syndrome * Patients receiving methotrexate or any TNF (tumor necrosis factor) antagonist therapy * Patients with chronic infections * Patients treated for a malignancy within the past 3 years * Patients with a latex allergy * Patients with an inner ear anomaly * Patients with retrocochlear pathology

Locations (1)

North Shore-LIJ Hearing and Speech Center

New Hyde Park, New York, United States

Outcomes

Primary Outcomes

To Assess the Potential Efficacy of Anakinra in Improving Hearing Thresholds in Corticosteroid-resistant Patients With Autoimmune Inner Ear Disease

The primary endpoint is to determine whether those treated with anakinra for 84 days demonstrate an improved hearing threshold compared with their pre-anakinra-treatment threshold. Audiometric thresholds will be compared to those treated with a prolonged corticosteroid taper and those that elect for no further treatment. The durability of the response will be measured over a total of 180 days.

Time frame: 180 days

Secondary Outcomes

Number of Serious Adverse Events Reported

To assess the number of Serious Adverse Events reported in any subject that received at least one injection dose of anakinra

Time frame: 84 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.